A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis

T. Saida, S. Kikuchi, Y. Itoyama, Q. Hao, T. Kurosawa, K. Nagato, D. Tang, L. Zhang-Auberson, Jun-Ichi Kira

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Fingolimod (FTY720) has previously shown clinical efficacy in phase II/III studies of predominantly Caucasian populations with multiple sclerosis (MS). Objectives: To report six-month efficacy and safety outcomes in Japanese patients with relapsing MS treated with fingolimod. Methods: In this double-blind, parallel-group, phase II study, 171 Japanese patients with relapsing MS were randomized to receive once-daily fingolimod 0.5 mg or 1.25 mg, or matching placebo for six months. The primary and secondary endpoints were the percentages of patients free from gadolinium (Gd)-enhanced lesions at months 3 and 6, and relapses over six months, respectively; safety outcomes were also assessed. Results: 147 patients completed the study. Higher proportions of patients were free from Gd-enhanced lesions at months 3 and 6 with fingolimod (0.5 mg: 70%, p = 0.004; 1.25 mg: 86%, p < 0.001) than with placebo (40%). Odds ratios for the proportions of relapse-free patients over six months favoured fingolimod versus placebo but were not significant. Adverse events related to fingolimod included transient bradycardia and atrioventricular block at treatment initiation, and elevated liver enzyme levels. Conclusions: This study demonstrated the clinical efficacy of fingolimod for the first time in Japanese patients with MS, consistent with the established effects of fingolimod in Caucasian patients.

Original languageEnglish
Pages (from-to)1269-1277
Number of pages9
JournalMultiple Sclerosis Journal
Volume18
Issue number9
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Multiple Sclerosis
Randomized Controlled Trials
Placebos
Gadolinium
Safety
Fingolimod Hydrochloride
Recurrence
Atrioventricular Block
Bradycardia
Double-Blind Method
Odds Ratio
Liver
Enzymes
Population

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. / Saida, T.; Kikuchi, S.; Itoyama, Y.; Hao, Q.; Kurosawa, T.; Nagato, K.; Tang, D.; Zhang-Auberson, L.; Kira, Jun-Ichi.

In: Multiple Sclerosis Journal, Vol. 18, No. 9, 01.01.2012, p. 1269-1277.

Research output: Contribution to journalArticle

Saida, T, Kikuchi, S, Itoyama, Y, Hao, Q, Kurosawa, T, Nagato, K, Tang, D, Zhang-Auberson, L & Kira, J-I 2012, 'A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis', Multiple Sclerosis Journal, vol. 18, no. 9, pp. 1269-1277. https://doi.org/10.1177/1352458511435984
Saida, T. ; Kikuchi, S. ; Itoyama, Y. ; Hao, Q. ; Kurosawa, T. ; Nagato, K. ; Tang, D. ; Zhang-Auberson, L. ; Kira, Jun-Ichi. / A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. In: Multiple Sclerosis Journal. 2012 ; Vol. 18, No. 9. pp. 1269-1277.
@article{84bda246d4204bab89eb158440367585,
title = "A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis",
abstract = "Background: Fingolimod (FTY720) has previously shown clinical efficacy in phase II/III studies of predominantly Caucasian populations with multiple sclerosis (MS). Objectives: To report six-month efficacy and safety outcomes in Japanese patients with relapsing MS treated with fingolimod. Methods: In this double-blind, parallel-group, phase II study, 171 Japanese patients with relapsing MS were randomized to receive once-daily fingolimod 0.5 mg or 1.25 mg, or matching placebo for six months. The primary and secondary endpoints were the percentages of patients free from gadolinium (Gd)-enhanced lesions at months 3 and 6, and relapses over six months, respectively; safety outcomes were also assessed. Results: 147 patients completed the study. Higher proportions of patients were free from Gd-enhanced lesions at months 3 and 6 with fingolimod (0.5 mg: 70{\%}, p = 0.004; 1.25 mg: 86{\%}, p < 0.001) than with placebo (40{\%}). Odds ratios for the proportions of relapse-free patients over six months favoured fingolimod versus placebo but were not significant. Adverse events related to fingolimod included transient bradycardia and atrioventricular block at treatment initiation, and elevated liver enzyme levels. Conclusions: This study demonstrated the clinical efficacy of fingolimod for the first time in Japanese patients with MS, consistent with the established effects of fingolimod in Caucasian patients.",
author = "T. Saida and S. Kikuchi and Y. Itoyama and Q. Hao and T. Kurosawa and K. Nagato and D. Tang and L. Zhang-Auberson and Jun-Ichi Kira",
year = "2012",
month = "1",
day = "1",
doi = "10.1177/1352458511435984",
language = "English",
volume = "18",
pages = "1269--1277",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "9",

}

TY - JOUR

T1 - A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis

AU - Saida, T.

AU - Kikuchi, S.

AU - Itoyama, Y.

AU - Hao, Q.

AU - Kurosawa, T.

AU - Nagato, K.

AU - Tang, D.

AU - Zhang-Auberson, L.

AU - Kira, Jun-Ichi

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background: Fingolimod (FTY720) has previously shown clinical efficacy in phase II/III studies of predominantly Caucasian populations with multiple sclerosis (MS). Objectives: To report six-month efficacy and safety outcomes in Japanese patients with relapsing MS treated with fingolimod. Methods: In this double-blind, parallel-group, phase II study, 171 Japanese patients with relapsing MS were randomized to receive once-daily fingolimod 0.5 mg or 1.25 mg, or matching placebo for six months. The primary and secondary endpoints were the percentages of patients free from gadolinium (Gd)-enhanced lesions at months 3 and 6, and relapses over six months, respectively; safety outcomes were also assessed. Results: 147 patients completed the study. Higher proportions of patients were free from Gd-enhanced lesions at months 3 and 6 with fingolimod (0.5 mg: 70%, p = 0.004; 1.25 mg: 86%, p < 0.001) than with placebo (40%). Odds ratios for the proportions of relapse-free patients over six months favoured fingolimod versus placebo but were not significant. Adverse events related to fingolimod included transient bradycardia and atrioventricular block at treatment initiation, and elevated liver enzyme levels. Conclusions: This study demonstrated the clinical efficacy of fingolimod for the first time in Japanese patients with MS, consistent with the established effects of fingolimod in Caucasian patients.

AB - Background: Fingolimod (FTY720) has previously shown clinical efficacy in phase II/III studies of predominantly Caucasian populations with multiple sclerosis (MS). Objectives: To report six-month efficacy and safety outcomes in Japanese patients with relapsing MS treated with fingolimod. Methods: In this double-blind, parallel-group, phase II study, 171 Japanese patients with relapsing MS were randomized to receive once-daily fingolimod 0.5 mg or 1.25 mg, or matching placebo for six months. The primary and secondary endpoints were the percentages of patients free from gadolinium (Gd)-enhanced lesions at months 3 and 6, and relapses over six months, respectively; safety outcomes were also assessed. Results: 147 patients completed the study. Higher proportions of patients were free from Gd-enhanced lesions at months 3 and 6 with fingolimod (0.5 mg: 70%, p = 0.004; 1.25 mg: 86%, p < 0.001) than with placebo (40%). Odds ratios for the proportions of relapse-free patients over six months favoured fingolimod versus placebo but were not significant. Adverse events related to fingolimod included transient bradycardia and atrioventricular block at treatment initiation, and elevated liver enzyme levels. Conclusions: This study demonstrated the clinical efficacy of fingolimod for the first time in Japanese patients with MS, consistent with the established effects of fingolimod in Caucasian patients.

UR - http://www.scopus.com/inward/record.url?scp=84866021501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866021501&partnerID=8YFLogxK

U2 - 10.1177/1352458511435984

DO - 10.1177/1352458511435984

M3 - Article

VL - 18

SP - 1269

EP - 1277

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 9

ER -